Isointense model for the evaluation of tumor-specific MRI contrast agents.

An isointense model has been developed to evaluate the applicability of putative tumor-specific MRI contrast agents. Data for tissue relaxation measurements in the presence of Mn(III)TPPS4 are used to illustrate the model. The concentration of contrast agent in tumor tissue required for a tumor/normal tissue signal difference-to-noise ratio of 5 (delta SNR = 5) is determined for a T1 weighted pulse sequence and several hypothetical tumor/normal tissue pairs. The impact of various contrast agent characteristics including initial tumor/normal tissue relaxation values, differential uptake of contrast agent, and in vivo relaxivity are considered. Isointense tumor/normal tissue with longer initial relaxation times are shown to be more affected by the presence of contrast agent. In addition those with initially longer relaxation times have less rigorous requirements for tumor specificity. Typically, a normal tissue/tumor uptake ratio of 1:2 increases the concentration required for delta SNR = 5 by a factor of two compared to that of exclusive uptake in tumor. For the T1 weighted pulse sequence employed, the concentration required for delta SNR = 5 is shown to be linear with the inverse of in vivo relaxivity for the hypothetical tissues considered. The isointense model is also extended to predict the field dependence of tumor-specific contrast enhancement by Mn(III)TPPS4.
AuthorsT M Button, R J Fiel
JournalMagnetic resonance imaging (Magn Reson Imaging) 1988 May-Jun Vol. 6 Issue 3 Pg. 275-80 ISSN: 0730-725X [Print] UNITED STATES
PMID3398734 (Publication Type: Journal Article)
Chemical References
  • Contrast Media
  • Metalloporphyrins
  • Porphyrins
  • manganese(III)tetraphenylporphine sulfonate
  • Contrast Media
  • Evaluation Studies as Topic
  • Humans
  • Magnetic Resonance Imaging
  • Metalloporphyrins
  • Models, Biological
  • Neoplasms (diagnosis)
  • Porphyrins (pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: